Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer
Journal of Controlled Release · 2024-12 · 376 · 1014-1024
DOI: 10.1016/j.jconrel.2024.10.062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-12. Verfasst von Jiahui Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah…. Hauptthemen laut MEDLINE: Receptors, TNF-Related Apoptosis-Inducing Ligand, Colonic Neoplasms, Histone Deacetylase Inhibitors, Apoptosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Utah, National Institutes of Health.
Abstract (Originalsprache)
Death Receptor 5 (DR5) targeted therapies offer significant promise due to their pivotal role in mediating the extrinsic pathway of apoptosis. Despite DR5 overexpression in various malignancies and the potential of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), clinical applications of anti-DR5 monoclonal antibodies (mAbs) have been hampered by suboptimal outcomes potentially due to lack of receptor clustering. To address the limitation, we developed N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-based conjugates integrating multiple copies of DR5-targeting peptide (cyclic WDCLDNRIGRRQCVKL; cDR5) to enhance receptor clustering and apoptosis. Three conjugates with variable number of cDR5 were prepared and denoted as PH-cDR5 (high valence), PM-cDR5 (medium valence) and PL-cDR5 (low valence). Our studies in TRAIL-sensitive and resistant cancer cell lines demonstrated that the HPMA copolymer-peptide conjugates (P-cDR5) significantly improved DR5 receptor clustering and induced apoptosis effectively. In TRAIL-sensitive colon cancer cells (COLO205, HCT-116), P-cDR5 showed efficacy comparable to anti-DR5 mAb Drozitumab (DRO), but P-cDR5 outperformed DRO in TRAIL-resistant cells (HT-29), highlighting the importance of efficient receptor clustering. In COLO205 cells PM-cDR5 exhibited an IC50 of 94 pM, while PH-cDR5 had an even lower IC50 of 15 pM (based on cDR5 equivalent concentration), indicating enhanced potency of the multivalent HPMA copolymer-based system with a flexible polymer backbone in comparison with the IC50 for TRAIL at 0.12 nM. Combining P-cDR5 with valproic acid, a histone deacetylase inhibitor, resulted in further enhancement of apoptosis inducing efficacy, along with destabilizing mitochondrial membranes and increased sensitivity of TRAIL-resistant cells. These findings suggest that attaching multiple cDR5 peptides to a flexible water-soluble polymer carrier not only overcomes the limitations of previous designs but also offers a promising avenue for treating resistant cancers, pointing toward the need for further preclinical exploration and validation of this innovative strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
- Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA; Department of Biomedical Engineering,…
- Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: jiyuan.yang@utah.…
Förderung
- NCI NIH HHS
- University of Utah
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Li, J., Arnold, J., Sima, M., Al Faruque, H., Galang, J., Hu-Lieskovan, S., Kopeček, J., & Yang, J. (2024). Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. Journal of Controlled Release, 376, 1014-1024. https://doi.org/10.1016/j.jconrel.2024.10.062
Vancouver
Li J, Arnold J, Sima M, Al Faruque H, Galang J, Hu-Lieskovan S, et al. Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. Journal of Controlled Release. 2024;376:1014-1024. doi:10.1016/j.jconrel.2024.10.062
BibTeX
@article{Li2024,
author = {Li, Jiahui and Arnold, Jaden and Sima, Monika and Al Faruque, Hasan and Galang, Jacob and Hu-Lieskovan, Sophia and Kopeček, Jindřich and Yang, Jiyuan},
title = {Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer},
journal = {Journal of Controlled Release},
year = {2024},
volume = {376},
pages = {1014--1024},
doi = {10.1016/j.jconrel.2024.10.062}
}
EUVIMED